Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs

In a single-center study of venetoclax-based regimens in patients with newly diagnosed post–MPN-AML, median overall survival was 7 months among patients receiving frontline therapy (n =14) and 3 months for those with relapsed/refractory (R/R) disease (n = 17). During the initial treatment cycle, 83% of patients developed > grade 3 infection, with 14 patients experiencing severe hemorrhagic complications. Overall 4-week and 8-week mortality were 10% and 32%, respectively.